Pulse Biosciences (NASDAQ: PLSE) awards CTO 100,000-share RSU grant

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Pulse Biosciences, Inc. reported that its Compensation Committee granted Chief Technology Officer Darrin R. Uecker a restricted stock unit award covering 100,000 shares of common stock. The award recognizes his continued leadership of the company’s product development efforts for the treatment of atrial fibrillation.

The RSUs vest in full on the third anniversary of the grant date, subject to the terms of the grant agreement and the company’s Amended and Restated 2017 Equity Incentive Plan. This is an equity-based compensation grant designed to align the CTO’s incentives with long-term company performance.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

03/27/2026 - 04:32 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 23, 2026

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-37744	46-5696597
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On March 23, 2026, the Compensation Committee of the Board of Directors of Pulse Biosciences, Inc. (the “Company”) awarded the Company’s Chief Technology Officer, Darrin R. Uecker, for his continued leadership of the Company’s product development efforts for the treatment of atrial fibrillation, a grant of restricted stock units representing 100,000 shares of the Company’s common stock, par value $0.001. The grant to Mr. Uecker vests in full on the third anniversary of the date of grant, subject to the terms and conditions of the grant award agreement and the Company’s Amended and Restated 2017 Equity Incentive Plan.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PULSE BIOSCIENCES, INC.


Date: March 27, 2026	By:	/s/ Paul A. LaViolette
		Paul A. LaViolette
		President and Chief Executive Officer (Principal Executive Officer)

Source: View Original Filing on SEC EDGAR

FAQ

What executive compensation change did Pulse Biosciences (PLSE) disclose?

Pulse Biosciences disclosed that its Chief Technology Officer, Darrin R. Uecker, received a restricted stock unit grant for 100,000 shares. The award recognizes his leadership of product development for atrial fibrillation and vests on the third anniversary of the grant date under the 2017 Equity Incentive Plan.

How many restricted stock units did Pulse Biosciences (PLSE) grant to its CTO?

The CTO of Pulse Biosciences, Darrin R. Uecker, was granted restricted stock units representing 100,000 shares of common stock. These RSUs are subject to the company’s Amended and Restated 2017 Equity Incentive Plan and vest in full three years after the grant date if conditions are satisfied.

When do the new RSUs granted by Pulse Biosciences to its CTO vest?

The RSUs granted to Pulse Biosciences’ CTO vest in full on the third anniversary of the grant date. Vesting is subject to the terms and conditions of the grant award agreement and the company’s Amended and Restated 2017 Equity Incentive Plan governing this equity compensation.

Why did Pulse Biosciences (PLSE) grant RSUs to CTO Darrin Uecker?

Pulse Biosciences granted RSUs to CTO Darrin R. Uecker for his continued leadership of the company’s product development efforts for the treatment of atrial fibrillation. The award aligns his compensation with long-term company performance through equity tied to the company’s common stock.

Under which plan were the new Pulse Biosciences RSUs for the CTO issued?

The restricted stock units granted to Pulse Biosciences’ CTO were issued under the company’s Amended and Restated 2017 Equity Incentive Plan. This plan governs the terms, vesting conditions, and administration of equity awards such as RSUs granted to executives and other eligible participants.

Filing Exhibits & Attachments

4 documents